Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The development of the Community Deprivation Index and its application to accountable care organizations.

Health affairs scholar·2024

Same author

Methods for Estimating Costs for Stays at Inpatient Rehabilitation Facilities and Long-Term Care Hospitals.

Archives of physical medicine and rehabilitation·2024

Same author

Do Medicare Inpatient Rehabilitation Facility Patients' Self-care and Mobility Outcomes Vary by Dual Eligibility Status, Race and Ethnicity, Rural Residence, Socioeconomic Status, and Living Alone?

American journal of physical medicine & rehabilitation·2024

Same author

Hospital Transfer Rates among Long-Stay Nursing Home Residents: Variation by Day of the Week.

Journal of the American Medical Directors Association·2023

Same author

Outcomes for Long-Stay Nursing Facility Residents Following On-Site Acute Care under a CMS Initiative.

Journal of the American Medical Directors Association·2023

Same author

Characteristics and Outcomes of Medicare Patients Treated in Inpatient Rehabilitation Facilities: 2013-2018.

Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses·2023

Search research articles

Related Experiment Videos

Risk-adjustment system for the Medicare capitated ESRD program.

Jesse M Levy¹, John Robst, Melvin J Ingber

¹Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850, USA. jesse.levy@cms.hhs.gov

Health Care Financing Review

|February 13, 2007

Summary

Medicare is the primary payer for end-stage renal disease (ESRD) care. A new Medicare risk-adjustment system was developed to improve payments for ESRD patients in managed care plans.

Related Experiment Videos

Area of Science:

Health Services Research
Health Economics
Nephrology

Background:

Medicare is the main payer for U.S. end-stage renal disease (ESRD) patients.
Current law prohibits ESRD beneficiaries from enrolling in Medicare Advantage (MA) plans.
Managed care may offer benefits for ESRD patients, prompting interest in policy changes.

Purpose of the Study:

To describe a novel risk-adjustment system for Medicare payments.
To improve payment accuracy for ESRD beneficiaries in managed care settings.

Main Methods:

Development of a new risk-adjustment model for Medicare.
Incorporation of treatment status and comorbidities into the payment model.

Main Results:

The new model enhances current Medicare payment methodologies.
Payments are adjusted based on specific patient characteristics.

Conclusions:

The developed risk-adjustment system offers improved payment accuracy.
This system supports potential future integration of ESRD patients into managed care plans.